Multidrug Efflux Systems in Helicobacter cinaedi

  • Yuji Morita
    Department of Microbiology, School of Pharmacy, Aichi Gakuin University/ 1-100 Kusumoto, Chikusa, Nagoya, Aichi 464-8650, Japan
  • Junko Tomida
    Department of Microbiology, School of Pharmacy, Aichi Gakuin University/ 1-100 Kusumoto, Chikusa, Nagoya, Aichi 464-8650, Japan
  • Yoshiaki Kawamura
    Department of Microbiology, School of Pharmacy, Aichi Gakuin University/ 1-100 Kusumoto, Chikusa, Nagoya, Aichi 464-8650, Japan

書誌事項

公開日
2012-11-21
資源種別
journal article
権利情報
  • https://creativecommons.org/licenses/by/3.0/
DOI
  • 10.3390/antibiotics1010029
公開者
MDPI AG

説明

<jats:p>Helicobacter cinaedi causes infections, such as bacteremia, diarrhea and cellulitis in mainly immunocompromised patients. This pathogen is often problematic to analyze, and insufficient information is available, because it grows slowly and poorly in subculture under a microaerobic atmosphere. The first-choice therapy to eradicate H. cinaedi is antimicrobial chemotherapy; however, its use is linked to the development of resistance. Although we need to understand the antimicrobial resistance mechanisms of H. cinaedi, unfortunately, sufficient genetic tools for H. cinaedi have not yet been developed. In July 2012, the complete sequence of H. cinaedi strain PAGU 611, isolated from a case of human bacteremia, was announced. This strain possesses multidrug efflux systems, intrinsic antimicrobial resistance mechanisms and typical mutations in gyrA and the 23S rRNA gene, which are involved in acquired resistance to fluoroquinolones and macrolides, respectively. Here, we compare the organization and properties of the efflux systems of H. cinaedi with the multidrug efflux systems identified in other bacteria.</jats:p>

収録刊行物

  • Antibiotics

    Antibiotics 1 (1), 29-43, 2012-11-21

    MDPI AG

被引用文献 (2)*注記

もっと見る

参考文献 (65)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ